Herpesvirus Resistance

  • G. Boivin
  • W.L. Drew
Chapter
Part of the Infectious Disease book series (ID)

In addition to the treatment of established HCMV disease, antivirals have also been used to prevent such symptomatic episodes, especially in transplant recipients. The fi rst strategy, defined as prophylaxis, consists of administering an antiviral to patients during the fi rst 3 months or so after transplantation. The second strategy, referred to as “preemptive therapy”, consists of using short courses of antivirals only for high-risk patients on the basis of evidence of active viral replication (e.g., detection of early HCMV antigens such as the pp65 protein or suffi cient amounts of viral DNA/ mRNA) (8). These preventive strategies have shown efficacy in preventing HCMV disease in both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) patients (9–11). However, some studies suggest that “prevention” may only delay, rather than truly prevent, the onset of HCMV disease in predisposed patients (10, 12–15).

Keywords

Herpes Simplex Virus Hematopoietic Stem Cell Transplant Antimicrob Agent Human Cytomegalovirus Cytomegalovirus Retinitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Balfour HH, Jr. Antiviral drugs. N Engl J Med 1999;340:1255–1268PubMedCrossRefGoogle Scholar
  2. 2.
    Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1- (hydroxymethyl)ethoxy] methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985;82:2473–2477PubMedCrossRefGoogle Scholar
  3. 3.
    Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162–164PubMedCrossRefGoogle Scholar
  4. 4.
    Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811–2815PubMedCrossRefGoogle Scholar
  5. 5.
    Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalo-virus infection on their activities in host cells. Mol Pharmacol 1996;50:1502–1510PubMedGoogle Scholar
  6. 6.
    Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immu-nocompromised patients with cytomegalovirus retinitis. Drugs 1991;41:104–129PubMedCrossRefGoogle Scholar
  7. 7.
    Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother 1998;42:971–973PubMedGoogle Scholar
  8. 8.
    Boeckh M, Boivin G. Quantitation of cytomegalovirus: meth-odologic aspects and clinical applications. Clin Microbiol Rev 1998;11:533–5541PubMedGoogle Scholar
  9. 9.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407–414PubMedCrossRefGoogle Scholar
  10. 10.
    Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462–1470PubMedCrossRefGoogle Scholar
  11. 11.
    Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral gan-ciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002;185:854–860PubMedCrossRefGoogle Scholar
  12. 12.
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645–649PubMedCrossRefGoogle Scholar
  13. 13.
    Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999;28:618–623PubMedCrossRefGoogle Scholar
  14. 14.
    Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461–1464PubMedCrossRefGoogle Scholar
  15. 15.
    Zaia JA, GallezHawkins GM, Tegtmeier BR, et al. Late cytomega-lovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997;176:782–785PubMedCrossRefGoogle Scholar
  16. 16.
    Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253:8721–8727PubMedGoogle Scholar
  17. 17.
    Safrin S, Ashley R, Houlihan C, Cusick PS, Mills J. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS 1991;5:1107–1110PubMedCrossRefGoogle Scholar
  18. 18.
    Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutane-ous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551–555PubMedCrossRefGoogle Scholar
  19. 19.
    Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000;44:688–692PubMedCrossRefGoogle Scholar
  20. 20.
    Dankner WM, Scholl D, Stanat SC, Martin M, Sonke RL, Spector SA. Rapid antiviral DNA—DNA hybridization assay for human cytomegalovirus. J Virol Methods 1990;28:293–298PubMedCrossRefGoogle Scholar
  21. 21.
    Tatarowicz WA, Lurain NS, Thompson KD. In situ ELISA for the evaluation of antiviral compounds effective against human cytome-galovirus. J Virol Methods 1991;35:207–215PubMedCrossRefGoogle Scholar
  22. 22.
    Kesson A, Zeng F, Cunningham A, Rawlinson W. The use of flow cytometry to detect antiviral resistance in human cytomegalovirus. J Virol Methods 1998;71:177–186PubMedCrossRefGoogle Scholar
  23. 23.
    McSharry JM, Lurain NS, Drusano GL, et al. Flow cytometric determination of ganciclovir susceptibilities of human cytomega-lovirus clinical isolates. J Clin Microbiol 1998;36:958–964PubMedGoogle Scholar
  24. 24.
    Telenti A, Smith TF. Screening with a shell vial assay for antiviral activity against cytomegalovirus. Diagn Microbiol Infect Dis 1989;12:5–8PubMedCrossRefGoogle Scholar
  25. 25.
    Gerna G, Baldanti F, Zavattoni M, Sarasini A, Percivalle E, Revello MG. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antivir Res 1992;19:333–345PubMedCrossRefGoogle Scholar
  26. 26.
    Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998;177:770–773PubMedCrossRefGoogle Scholar
  27. 27.
    Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomega-lovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother 1998;42:2240–2244PubMedGoogle Scholar
  28. 28.
    Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003;187:777–784PubMedCrossRefGoogle Scholar
  29. 29.
    Gilbert C, Boivin G. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS 2003;17:337–341PubMedCrossRefGoogle Scholar
  30. 30.
    Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 2003;187:139–143PubMedCrossRefGoogle Scholar
  31. 31.
    Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclo-vir. J Infect Dis 2002;185:162–169PubMedCrossRefGoogle Scholar
  32. 32.
    Boivin G, Chou S, Quirk MR, Erice A, Jordan MC. Detection of ganciclovir resistance mutations and quantitation of cytomegalovi-rus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996;173:523–528PubMedGoogle Scholar
  33. 33.
    Wolf DG, Smith IL, Lee DJ, Freeman WR, Flores Aguilar M, Spector SA. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995;95:257–263PubMedCrossRefGoogle Scholar
  34. 34.
    Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phospho-transferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576–583PubMedGoogle Scholar
  35. 35.
    Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytome-galovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995;39:1204–1205PubMedGoogle Scholar
  36. 36.
    Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001;184:1598–1602PubMedCrossRefGoogle Scholar
  37. 37.
    Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5:88–114PubMedCrossRefGoogle Scholar
  38. 38.
    Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymer-ase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999;43:1500–1502PubMedGoogle Scholar
  39. 39.
    Lurain NS, Weinberg A, Crumpacker CS, Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 2001;45:2775–2780PubMedCrossRefGoogle Scholar
  40. 40.
    Cihlar T, Fuller M, Cherrington J. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998;72:5927–5936PubMedGoogle Scholar
  41. 41.
    Baldanti F, Silini E, Sarasini A, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995;69:796–800PubMedGoogle Scholar
  42. 42.
    Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390–1395PubMedGoogle Scholar
  43. 43.
    Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997;176:786–789PubMedCrossRefGoogle Scholar
  44. 44.
    Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003;188:32–39PubMedCrossRefGoogle Scholar
  45. 45.
    Drew WL, Stempien MJ, Andrews J, et al. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis 1999;179:1352–1355PubMedCrossRefGoogle Scholar
  46. 46.
    Chou S, Marousek G, Parenti DM, et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998;178:526–530PubMedGoogle Scholar
  47. 47.
    Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J Infect Dis 1996;173:1481–1484PubMedGoogle Scholar
  48. 48.
    Smith IL, Taskintuna I, Rahhal FM, et al. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch Ophthalmol 1998;116:178–185PubMedGoogle Scholar
  49. 49.
    Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalo-virus mutations associated with ganciclovir resistance in cerebro-spinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995;39:2552–2554PubMedGoogle Scholar
  50. 50.
    Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716–719PubMedGoogle Scholar
  51. 51.
    Drew W. Cytomegalovirus Disease in the Highly Active Antiretroviral Therapy Era. Curr Infect Dis Rep 2003;5:257–265PubMedCrossRefGoogle Scholar
  52. 52.
    Nichols W, Boeckh M. Cytomegalovirus Infections. Curr Treat Opt Infect Dis 2001;3:78–91Google Scholar
  53. 53.
    Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclo-vir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002;21:1274–1282PubMedCrossRefGoogle Scholar
  54. 54.
    Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalo-virus infection after lung transplantation. Transplant 1999;68:1272–1279CrossRefGoogle Scholar
  55. 55.
    Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovi-rus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002;185:20–27PubMedCrossRefGoogle Scholar
  56. 56.
    Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002;186:760–768PubMedCrossRefGoogle Scholar
  57. 57.
    Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004;189:1615–1618PubMedCrossRefGoogle Scholar
  58. 58.
    Baldanti F, Lilleri D, Campanini G, et al. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J Antimicrob Chemother 2004;53:536–539PubMedCrossRefGoogle Scholar
  59. 59.
    Benz C, Holz G, Michel D, et al. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient. Transplant 2003;75:724–727CrossRefGoogle Scholar
  60. 60.
    Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866–872PubMedCrossRefGoogle Scholar
  61. 61.
    Gilbert C, Roy J, Bélanger R, et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2001;45:3669–3671PubMedCrossRefGoogle Scholar
  62. 62.
    Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867–874PubMedCrossRefGoogle Scholar
  63. 63.
    Erice A, Borrell N, Li W, Miller WJ, Balfour HH, Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 1998;178:531–534PubMedGoogle Scholar
  64. 64.
    Michel D, Hohn S, Haller T, Jun D, Mertens T. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J Med Virol 2001;65:70–76PubMedCrossRefGoogle Scholar
  65. 65.
    Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:289–291PubMedCrossRefGoogle Scholar
  66. 66.
    Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovi-rus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000;96:3286–3289PubMedGoogle Scholar
  67. 67.
    Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T, Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998;178:535–538PubMedGoogle Scholar
  68. 68.
    Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003;101:463–465PubMedCrossRefGoogle Scholar
  69. 69.
    Jabs DA, Martin BK, Forman MS, et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retini-tis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol 2001;132:700–710PubMedCrossRefGoogle Scholar
  70. 70.
    Drew WL, Paya C V, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 2001;1:307–312PubMedCrossRefGoogle Scholar
  71. 71.
    Chou S, Meichsner CL. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob Agents Chemother 2000;44:183–185PubMedCrossRefGoogle Scholar
  72. 72.
    Baldanti F, Underwood MR, Talarico CL, et al. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 1998;42:444–446PubMedGoogle Scholar
  73. 73.
    Baldanti F, Michel D, Simoncini L, et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recom-binant vaccinia virus system. Antiviral Res 2002;54:59–67PubMedCrossRefGoogle Scholar
  74. 74.
    Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998;248:382–393PubMedCrossRefGoogle Scholar
  75. 75.
    Mousavi-Jazi M, Schloss L, Drew WL, et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001;23:1–15PubMedCrossRefGoogle Scholar
  76. 76.
    Erice A, Gil-Roda C, Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175:1087–1092PubMedCrossRefGoogle Scholar
  77. 77.
    Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001;183:333–337PubMedCrossRefGoogle Scholar
  78. 78.
    Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganci-clovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997;176:69–77PubMedCrossRefGoogle Scholar
  79. 79.
    Gerna G, Sarasini A, Lilleri D, et al. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovi-rus infection with ganciclovir in transplant recipients. J Infect Dis 2003;188:1639–1647PubMedCrossRefGoogle Scholar
  80. 80.
    Hu H, Jabs DA, Forman MS, et al. Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J Infect Dis 2002;185:861–867PubMedCrossRefGoogle Scholar
  81. 81.
    Liu W, Kuppermann BD, Martin DF, Wolitz RA, Margolis TP. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. J Infect Dis 1998;177:1176–1181PubMedCrossRefGoogle Scholar
  82. 82.
    Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002;34:1337–1341PubMedCrossRefGoogle Scholar
  83. 83.
    Studies, AIDS. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retini-tis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996;114:23–33Google Scholar
  84. 84.
    Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000;182:290–293PubMedCrossRefGoogle Scholar
  85. 85.
    Gaudreau A, Hill E, Balfour HH, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998;178:297–303PubMedGoogle Scholar
  86. 86.
    Coen DM, Kosz-Vnenchak M, Jacobson JG, et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 1989;86:4736–4740PubMedCrossRefGoogle Scholar
  87. 87.
    Tenser RB, Hay KA, Edris WA. Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1. J Virol 1989;63:2861–2865PubMedGoogle Scholar
  88. 88.
    Wilcox CL, Crnic LS, Pizer LI. Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymi-dine kinase-negative mutant. Virology 1992;187:348–352PubMedCrossRefGoogle Scholar
  89. 89.
    Martin JL, Ellis MN, Keller PM, et al. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrobial Agents and Chemotherapy 1985;28:181–187PubMedGoogle Scholar
  90. 90.
    Sasadeusz JJ, Sacks SL. Spontaneous reactivation of thymi-dine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? J Infect Dis 1996;174:476–482PubMedGoogle Scholar
  91. 91.
    Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001;75:3105–3110PubMedCrossRefGoogle Scholar
  92. 92.
    Chibo D, Druce J, Sasadeusz J, Birch C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004;61:83–91PubMedCrossRefGoogle Scholar
  93. 93.
    Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003;77:7820–7829PubMedCrossRefGoogle Scholar
  94. 94.
    Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993;Suppl:58–66Google Scholar
  95. 95.
    Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293–296PubMedCrossRefGoogle Scholar
  96. 96.
    Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH, Jr. Herpes simplex virus resistant to acy-clovir. A study in a tertiary care center. Ann Intern Med 1990;112:416–422Google Scholar
  97. 97.
    Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193–196PubMedGoogle Scholar
  98. 98.
    Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991;180:793–797PubMedCrossRefGoogle Scholar
  99. 99.
    Sarisky RT, Crosson P, Cano R, et al. Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility. J Clin Virol 2002;23:191–200PubMedCrossRefGoogle Scholar
  100. 100.
    Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003;26:29–37PubMedCrossRefGoogle Scholar
  101. 101.
    Fillet AM, Dumont B, Caumes E, et al. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Vir 1998;55:250–254CrossRefGoogle Scholar
  102. 102.
    Saint-Leger E, Caumes E, Breton G, et al. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001;33:2061–2067PubMedCrossRefGoogle Scholar
  103. 103.
    Sahli R, Andrei G, Estrade C, Snoeck R, Meylan PR. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame. Antimicrob Agents Chemother 2000;44:873–878PubMedCrossRefGoogle Scholar
  104. 104.
    Whitley RJ, Gnann JW, Jr. Acyclovir: a decade later. N Engl J Med 1992;327:782–789PubMedCrossRefGoogle Scholar
  105. 105.
    Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42:868–872PubMedGoogle Scholar
  106. 106.
    Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclo-vir. J Infect Dis 1994;169:1338–1341PubMedGoogle Scholar
  107. 107.
    Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988;260:201–206Google Scholar
  108. 108.
    Boon RJ, Bacon TH, Robey HL, et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey. J Antimicrob Chemother 2000;46:1051PubMedCrossRefGoogle Scholar
  109. 109.
    Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004;42:242–249PubMedCrossRefGoogle Scholar
  110. 110.
    Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993;329:1777–1782PubMedCrossRefGoogle Scholar
  111. 111.
    Swetter SM, Hill EL, Kern ER, et al. Chronic vulvar ulcera-tion in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis 1998;177:543–550PubMedCrossRefGoogle Scholar
  112. 112.
    Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322–2328PubMedGoogle Scholar
  113. 113.
    Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990;161:1078–1084PubMedGoogle Scholar
  114. 114.
    Morfin F, Thouvenot D, Aymard M, Souillet G. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. J Med Virol 2000;62:247–250PubMedCrossRefGoogle Scholar
  115. 115.
    Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982;96:265–269PubMedGoogle Scholar
  116. 116.
    Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother 1993;37:357–359PubMedGoogle Scholar
  117. 117.
    Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000;31:927–935PubMedCrossRefGoogle Scholar
  118. 118.
    Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39 Suppl 5:S248–S257PubMedCrossRefGoogle Scholar
  119. 119.
    Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76–80PubMedCrossRefGoogle Scholar
  120. 120.
    DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009–1016PubMedCrossRefGoogle Scholar
  121. 121.
    Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000;181:2055–2058PubMedCrossRefGoogle Scholar
  122. 122.
    Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploi-dentical hematopoietic progenitor cell transplantation. Blood 2002;99:1085–1088PubMedCrossRefGoogle Scholar
  123. 123.
    Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999;43:2412–2416PubMedGoogle Scholar
  124. 124.
    Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH, Jr. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170:68–75PubMedGoogle Scholar
  125. 125.
    Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol 1989;70:375–382PubMedCrossRefGoogle Scholar
  126. 126.
    Bendel AE, Gross TG, Woods WG, Edelman CK, Balfour HH, Jr. Failure of foscarnet in disseminated herpes zoster. Lancet 1993;341:1342PubMedCrossRefGoogle Scholar
  127. 127.
    Fillet AM, Visse B, Caumes E, Dumont B, Gentilini M, Huraux JM. Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 1995;21:1348–1349PubMedGoogle Scholar
  128. 128.
    Hwang CB, Ruffner KL, Coen DM. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymer-ase gene confers drug resistance. J Virol 1992;66:1774–1776PubMedGoogle Scholar
  129. 129.
    Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis 1999;180:487–490PubMedCrossRefGoogle Scholar
  130. 130.
    Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991;115:19–21PubMedGoogle Scholar
  131. 131.
    Bestman-Smith J, Boivin G. Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. J Med Virol 2002:67:88–91PubMedCrossRefGoogle Scholar
  132. 132.
    Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989;320:297–300PubMedCrossRefGoogle Scholar
  133. 133.
    Erlich KS, Jacobson MA, Koehler JE, et al. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med 1989;110:710–713Google Scholar
  134. 134.
    Engel JP, Englund JA, Fletcher C V, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 1990;263:1662–1664PubMedCrossRefGoogle Scholar
  135. 135.
    Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892–898PubMedCrossRefGoogle Scholar
  136. 136.
    Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994;170:570–572PubMedGoogle Scholar
  137. 137.
    Kopp T, Geusau A, Rieger A, Stingl G. Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient. Br J Dermatol 2002;147:134–138PubMedCrossRefGoogle Scholar
  138. 138.
    Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 2003;21:311–320PubMedGoogle Scholar
  139. 139.
    Kessler HA, Hurwitz S, Farthing C, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutane-ous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:147–152Google Scholar
  140. 140.
    Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994;18:570–578PubMedGoogle Scholar
  141. 141.
    Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:187–191PubMedGoogle Scholar
  142. 142.
    Duan J, Liuzzi M, Paris W, et al. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo. Antimicrob Agents Chemother 1998;42:1629–1635PubMedGoogle Scholar
  143. 143.
    Liuzzi M, Deziel R, Moss N, et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 1994;372:695–698PubMedCrossRefGoogle Scholar
  144. 144.
    McSharry JJ, McDonough A, Olson B, et al. Susceptibilities of human cytomegalovirus clinical isolates to BAY38–4766, BAY43–9695, and ganciclovir. Antimicrob Agents Chemother 2001;45:2925–2927PubMedCrossRefGoogle Scholar
  145. 145.
    Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004;190:499–503PubMedCrossRefGoogle Scholar
  146. 146.
    Emery VC, Hassan-Walker AF. Focus on new drugs in development against human cytomegalovirus. Drugs 2002;62:1853–1858PubMedCrossRefGoogle Scholar
  147. 147.
    Michel D, Mertens T. The UL97 protein kinase of human cytome-galovirus and homologues in other herpesviruses: impact on virus and host. Biochim Biophys Acta 2004;1697:169–180PubMedGoogle Scholar
  148. 148.
    Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002;46:2373–2380PubMedCrossRefGoogle Scholar
  149. 149.
    Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47:1334–1342PubMedCrossRefGoogle Scholar
  150. 150.
    Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46:2365–2372PubMedCrossRefGoogle Scholar
  151. 151.
    Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002;46:2969–2976PubMedCrossRefGoogle Scholar
  152. 152.
    Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 2003;77:905–914PubMedCrossRefGoogle Scholar
  153. 153.
    Chou S, Marousek GI, Senters AE, Davis MG, Biron KK. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004;78:7124–7130PubMedCrossRefGoogle Scholar
  154. 154.
    Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC. Resistance of human cytomegalovirus to the benzim-idazole l-ribonucleoside maribavir maps to UL27. J Virol 2003;77:11499–11506PubMedCrossRefGoogle Scholar
  155. 155.
    Reefschlaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38–4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001;48:757–767PubMedCrossRefGoogle Scholar
  156. 156.
    Underwood MR, Ferris RG, Selleseth DW, et al. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 2004;48:1647–1651PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • G. Boivin
    • 1
  • W.L. Drew
    • 2
  1. 1.Centre de Recherche en Infectiologie of Université LavalQuébec CityCanada
  2. 2.Laboratory Medicine and Medicine, Director, Clinical Virology LaboratoryUniversity of California — San FranciscoSan FranciscoUSA

Personalised recommendations